Scarica l'app Stockscreener
11.70
1.76%
-0.21
Dopo l'orario di chiusura:
11.70
Precedente Chiudi:
$11.91
Aprire:
$12.295
Volume 24 ore:
1.40M
Relative Volume:
0.81
Capitalizzazione di mercato:
$854.92M
Reddito:
-
Utile/perdita netta:
$-148.00M
Rapporto P/E:
-2.6411
EPS:
-4.4299
Flusso di cassa netto:
$-135.66M
1 W Prestazione:
-7.22%
1M Prestazione:
-2.09%
6M Prestazione:
+128.52%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.52
$12.29
Intervallo di 1 settimana:
$11.52
$12.96
Portata 52W:
$3.76
$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Nome
Helus Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HELP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
11.70 | 921.41M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | TD Cowen | Buy |
| 2026-02-02 | Iniziato | Jefferies | Buy |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Borsa (HELP) Ultime notizie
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push - TipRanks
Cybin rebrands to Helus Pharma, ticker symbol unchanged By Investing.com - Investing.com Nigeria
Helus Pharma (HELP) Officially Changes Legal Name from Cybin Inc. on October 1, 2026 - GuruFocus
Helus Pharma Announces Completion of Legal Name ChangeThu, 10/01/202607:30 - Helus Pharma
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - ca.finance.yahoo.com
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Cybin (CYBN) Presented 12 Month HLP003 Efficacy Data At A Psychiatry Congress - Simply Wall Street
Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention? - Yahoo Finance
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - Yahoo Finance
Helus Pharma at TD Cowen summit: late-stage psychedelic bet takes shape - Investing.com Australia
Cybin Inc. at TD Cowen Novel Mechanisms in Neuropsychiatry Conference (Virtual) Transcript - GuruFocus
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
HELP News Today | Why did Cybin stock go up today? $HELP - MarketBeat
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change - Investing News Network
Helus Pharma shareholders approve name change from Cybin Inc. By Investing.com - Investing.com Canada
Helus Pharma Shareholders Approve Name Change and Governance Resolutions - TipRanks
Helus Pharma shareholders approve name change from Cybin Inc. - Investing.com
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - Quiver Quantitative
Helus Pharma (HELP.NE) Shareholders Approve Legal Name Change from Cybin Inc., Directors Elected at Annual Meeting - kalkine.ca
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - MarketBeat
Cybin Inc. Annual Shareholders Meeting Transcript - GuruFocus
Phase 3 Depression Data Could Define The Case For Cybin Stock - simplywall.st
Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast - Stock Titan
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry SummitMon, 09/21/202617:15 - Helus Pharma
Helus Pharma (HELP.NE) CEO to Join TD Cowen Neuropsychiatry Summit Fireside Chat on September 23 - kalkine.ca
Cybin highlights Phase 3 psychedelic depression drug | HELP SEC FilingForm 6-K - Stock Titan
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 - investingnews.com
Helus Pharma presents data on depression drug candidate HLP003 By Investing.com - Investing.com Canada
Helus Pharma (HELP) Showcases Key HLP003 Data at Psych Congress 2026 Amid High Valuation Metrics - GuruFocus
A potential depression treatment has 12-month efficacy results. Helus Pharma is testing it in a late-stage study. - Stock Titan
Barclays Sees Buying Opportunity in Helus Pharma (HELP) Amid Sha - GuruFocus
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 - Yahoo Finance
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances - Yahoo Finance
Helus Pharma Inc (HELP) Stock Price, Quote, News & History - benzinga.com
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results - TradingView
HELP Initiates Coverage On by Barclays -- Rating Set to Overweig - GuruFocus
Helus Pharma at Morgan Stanley conference: a broader depression bet By Investing.com - Investing.com Nigeria
Helus Pharma at Morgan Stanley conference: a broader depression bet - Investing.com
Cybin Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma Inc Azioni (HELP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Helus Pharma Inc Azioni (HELP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| So Eric H. L. | Executive Chair |
Sep 08 '26 |
Buy |
12.39 |
100,000 |
1,238,670 |
4,465,014 |
| So Eric H. L. | Executive Chair |
Sep 04 '26 |
Buy |
12.09 |
100,000 |
1,208,900 |
4,365,014 |
| Glavine Paul | Chief Growth Officer |
Sep 03 '26 |
Buy |
11.78 |
100,000 |
1,178,280 |
4,171,252 |
| So Eric H. L. | Executive Chair |
Sep 01 '26 |
Buy |
11.80 |
95,000 |
1,121,475 |
4,265,014 |
| Glavine Paul | Chief Growth Officer |
Aug 31 '26 |
Buy |
11.59 |
90,000 |
1,042,677 |
4,071,252 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):